Secukinumab treatment of Parry-Romberg syndrome

Sideris, Emily; Zwaan, Sally de

doi:10.1016/j.jdcr.2020.07.036

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the increased percentage of Th17, known to be involved in the pathogenesis of multiple autoimmune diseases, seems to be counterbalanced by the rise in Treg, which, contrariwise, protects from auto-aggression and tissue damage. Notably, our finding supports the use of anti-IL17 receptor monoclonal antibody in PRS patients, as suggested by Sideris et al, who successfully tested secukinumab in a PRS patient [ 22 ]. Another anti-IL17 receptor monoclonal antibody, brodalumab, is under investigation in two different clinical trials on systemic sclerosis (phase III clinical trial Clinicaltrials.gov identifier: NCT03957681; phase I clinical trial Clinicaltrials.gov identifier: NCT04368403).…”

Section: Discussionsupporting

confidence: 88%

Immunological Profiles in Parry–Romberg Syndrome: A Case–Control Study

Saulle,

Gidaro,

Donadoni

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Parry–Romberg syndrome (PRS) is a rare craniofacial disorder. The aim of this study is to provide information on the immunological profile of this pathology. Since PRS can be included in a wider spectrum of sclerodermic diseases, we propose a case–control study comparing a patient affected by PRS with one with a diagnosis of scleroderma, herein used as control (CTR). Methods: B lymphocyte, T lymphocyte, and monocyte phenotypes and functions were assessed by flow cytometry in influenza (Flu)- or anti cluster differentiation (CD)3/CD28-stimulated peripheral blood mononuclear cells (PBMCs). Cytokine concentration was evaluated as well in PBMC supernatants, plasma, and saliva by Luminex assay. Results: T and B lymphocytes were similarly activated in unstimulated PRS and CTR cells but differed following antigen stimulation. T helper (Th)17 lymphocytes were expanded in PRS compared to CTR; this increase correlated with higher interleukin (IL)-17 concentration. Conclusions: Our case–control study is the first to compare the immunological profiles of PRS and scleroderma patients. The higher percentage of Th17 cells in PRS suggests the use of anti-IL17 receptor monoclonal antibody in this rare disease; however, further studies with larger numbers of patients are needed to confirm our findings.

show abstract

Section: Discussionsupporting

confidence: 88%